ArticleScientific reports2025
The examination of in vitro photosensitizing efficacy of aloe-emodin loaded liposome following photodynamic therapy on melanoma cell lines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of aloe extracts as a photosensitizer in antimicrobial photodynamic therapy againstBioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study focused on investigating the enhanced photoactive properties of liposomal aloe-emodin for photodynamic treatment (PDT). Aloe-emodin (A-E) was encapsulated in liposomes by using the copper ion gradient method. This study aimed to highlight the function of naturally occurring photoactive plant-based derivatives in liposomal formulations as simple alternative photosensitizers (PS) for melanoma photodynamic therapy (PDT). Furthermore, we aimed to show that phototoxic chemicals loaded into liposomes are less cytotoxic than non-encapsulated molecules, which we used in our previous study. To assess the effectiveness of liposome aloe-emodin as a photosensitizer in PDT on melanoma cell lines, we performed cellular uptake by flow cytometry, MTT assay to measure the cytotoxicity of a natural compound, wound healing assay, ROS analysis by confocal microscopy, ROS analysis by flow cytometry, immunocytochemistry staining to measure the level of apoptotic proteins, and Real-Time PCR gene expression analysis. The melanoma cells showed increased phototoxicity after therapy compared to the normal cells in the MTT assay. Moreover, liposome aloe-emodin-based photodynamic therapy resulted in an increased ratio of apoptotic cells, increased ROS levels, and increased or decreased gene expression. This study also demonstrated that aloe-emodin encapsulated in liposomes significantly decreased melanoma cell motility following PDT treatment. In conclusion, our study provides evidence that aloe-emodin-mediated PDT exhibits potential for clinical development as a novel, safe, and effective photosensitizer for melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.